Arcutis Biotherapeutics
ARQT
168 hedge funds and large institutions have $1.24B invested in Arcutis Biotherapeutics in 2024 Q1 according to their latest regulatory filings, with 59 funds opening new positions, 52 increasing their positions, 40 reducing their positions, and 23 closing their positions.
500% more funds holding in top 10
Funds holding in top 10: 1 → 6 (+5)
257% more capital invested
Capital invested by funds: $347M → $1.24B (+$892M)
157% more first-time investments, than exits
New positions opened: 59 | Existing positions closed: 23
30% more repeat investments, than reductions
Existing positions increased: 52 | Existing positions reduced: 40
26% more funds holding
Funds holding: 133 → 168 (+35)
5.04% less ownership
Funds ownership: 113.75% → 108.71% (-5%)
42% less call options, than puts
Call options by funds: $6.39M | Put options by funds: $11.1M
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
State Street
Boston,
Massachusetts
|
+$54.2M |
| 2 |
GGHC
Gilder Gagnon Howe & Co
New York
|
+$31.6M |
| 3 |
Jennison Associates
New York
|
+$23.2M |
| 4 |
CAM
Cormorant Asset Management
Boston,
Massachusetts
|
+$15.9M |
| 5 |
Citadel Advisors
Miami,
Florida
|
+$14.3M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Morgan Stanley
New York
|
-$60.9M |
| 2 |
Millennium Management
New York
|
-$16.3M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$8.72M |
| 4 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.07M |
| 5 |
BCLSI
Bain Capital Life Sciences Investors
Boston,
Massachusetts
|
-$7.38M |
ARQT Hedge Fund Activity: Q1 2024 in Review
168 of the 6,942 institutional investors tracked by Wall St. Rank reported a position in Arcutis Biotherapeutics (ARQT) for Q1 2024, worth a combined $1.24B — up 257% from $347M a quarter earlier.
Buyers outnumbered sellers: 59 funds opened new ARQT positions and 23 closed out — a net gain of 36 holders — while 52 added to existing stakes and 40 trimmed.
The largest buyer was State Street, adding an estimated $54.2M. The largest seller was Morgan Stanley, cutting an estimated $60.9M.
- 168 institutional investors held Arcutis Biotherapeutics (ARQT) as of Q1 2024, up from 133 in Q4 2023.
- Funds reported $1.24B of Arcutis Biotherapeutics stock for Q1 2024, up 257% quarter-over-quarter.
- 59 funds opened new Arcutis Biotherapeutics positions in Q1 2024 and 23 closed out, a net change of +36 holders.
- The largest Arcutis Biotherapeutics buyer in Q1 2024 was State Street, an estimated $54.2M added.
- The largest Arcutis Biotherapeutics seller in Q1 2024 was Morgan Stanley, an estimated $60.9M sold.
Based on aggregated 13F filings for Q1 2024.